Big Sky Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Triglycerides and Triglyceride-Rich Particles in Health and Disease (A3)


Organizer(s) Robert H. Eckel, Ira J. Goldberg and Ruth McPherson
January 9—14, 2010
Big Sky Resort • Big Sky, Montana USA
Abstract Deadline: Sep 15, 2009
Late Abstract Deadline: Oct 12, 2009
Scholarship Deadline: Sep 15, 2009
Early Registration Deadline: Nov 9, 2009

Supported by The Directors' Fund

Summary of Meeting:
Triglycerides are important storage molecules that play important roles in lipid and lipoprotein metabolism, insulin action, energy balance, and atherosclerosis. The purpose of this meeting will be to critically examine the broad spectrum of triglyceride biology from the molecular biology of triglyceride biosynthesis in the liver and intestine to lipoprotein assembly and secretion to lipid fuel partitioning to adipose tissue, muscle and the liver. A discussion of the regulation of free fatty acid flux from adipose tissue to the liver by insulin and pro- and anti-inflammatory cytokines will precede a detailed coverage of chylomicron and VLDL transport, intravascular lipolysis and tissue-specific lipid partitioning. A transition to the science and medicine of triglycerides will then occur with expected updates on the understanding of the genetic basis of disorders of triglyceride-rich lipoprotein metabolism and the pathogenesis of atherosclerosis that relate specifically to circulating triglyceride-rich particles. The clinical relevance of hypertriglyceridemia, new insights into the mechanisms of pharmacological treatment of hypertriglyceridemia, and clinical trial evidence pro and con that triglyceride lowering reduces cardiovascular disease risk will follow. The meeting should attract basic, clinical, and population scientists from academia and industry, and will deal with the many issues that remain unclear or controversial surrounding triglycerides and triglyceride rich particles in health and disease.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SATURDAY, JANUARY 9

15:00—19:30
Registration

Lower Atrium
18:30—19:30
Refreshments

Lower Atrium
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Gallatin
Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Increased Assembly and Secretion of Triglyceride-Rich Lipoproteins in Insulin Resistance: Greasing the Path to Atherosclerosis


SUNDAY, JANUARY 10

07:00—08:00
Breakfast

Jefferson/Madison
08:00—08:15
Welcome and Scientific Introduction

Gallatin
Robert H. Eckel, University of Colorado Denver, Anschutz Medical Campus, USA
Triglycerides in Health and Disease

08:15—11:30
Molecular/Cell Biology and Physiology of Triglyceride Synthesis and TG-Rich Lipoprotein Assembly and Secretion
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Mats Rudling, Karolinska Institutet, Sweden

* Douglas G. Mashek, University of Minnesota, USA

Rosalind A. Coleman, University of North Carolina at Chapel Hill, USA
Metabolic Channeling and Control of Fatty Acid Metabolism

Bart Staels, Institut Pasteur de Lille, Université Lille, France
Nuclear Receptor Control of Triglyceride Metabolism

Edward A. Fisher, New York University School of Medicine, USA
Omega-3 Fatty Acids and Lipoprotein Metabolism: Mechanistic Basis for their Clinical Effects

Mark D. Erion, Janssen Pharmaceutical, USA
Reduction in Plasma and Liver Triglycerides with a Liver-Targeted Thyroid Hormone Receptor-beta Agonist

John M. Stafford, Vanderbilt University, USA
Short Talk: Impaired Inactivation of FoxO1 Contributes to Glucose-Mediated Increases in Serum VLDL

J. Brandon Dixon, Georgia Institute of Technology, USA
Short Talk: Quantifying the Functional Transport of Lipoproteins by Lymphatic Endothelial Cells

11:30
On Own for Lunch and Recreation

09:20—09:40
Coffee Break

Lower Atrium
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Regulation of Lipolysis in Man and Rodents
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Miklos Péterfy, Cedars-Sinai Medical Center, USA

* Richard Lehner, University of Alberta, Canada

Rudolf Zechner, University of Graz, Austria
Intracellular Lipolysis and the Regulation of Lipid and Lipoprotein Metabolism

Susan K. Fried, Icahn School of Medicine at Mount Sinai, USA
Adipokines and Lipolysis in Human Obesity

Samuel Klein, Washington University School of Medicine, USA
Therapeutic Implications of Adipose Tissue and Hepatic Lipid Metabolism in Obesity

Janna A. van Diepen, University Medical Center St. Radboud, Netherlands
Short Talk: Hepatocyte-Specific Inflammation Enhances VLDL Production in Mice

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison

MONDAY, JANUARY 11

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:15
Chylomicron and VLDL Transport, Lipolysis and Tissue-Specific Lipid Partitioning
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Andre Bensadoun, Cornell University, USA

* Rudolf Zechner, University of Graz, Austria

Ira J. Goldberg, New York University, USA
LPL Mediated Lipid Uptake

Nada A. Abumrad, Washington University, USA
Free Fatty Acid Uptake and Intracellular Trafficking: Evolving Concepts

Keith N. Frayn, University of Oxford, UK
Triglyceride Uptake into Human Adipose Tissue

Stephen G. Young, University of California, Los Angeles, USA
An Endothelial Cell Protein Required for the Lipolytic Processing of Triglyceride-Rich Lipoproteins

Jason A. Magida, The Salk Institute, USA
Short Talk: Genetic Heart Disease Results in a Diabetic Phenotype via Reduced Clearance of VLDL-Triglycerides

Douglas G. Mashek, University of Minnesota, USA
Short Talk: Hepatic Adipose Triglyceride Lipase (ATGL) Alters Hepatic Triglyceride Turnover, Fatty Acid Channeling and PPAR-alpha Activity

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Jefferson/Madison
13:00—22:00
Poster Viewing

Jefferson/Madison
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Genetics and Pathophysiology of Disorders of TG-Rich Lipoprotein Metabolism
Meeting has ended...abstracts no longer viewable online.

Gallatin
* John D. Brunzell, University of Washington, USA

* Leanne Hodson, University of Oxford, UK

Ruth McPherson, University of Ottawa Heart Institute, Canada
Triglycerides and CAD Risk: Insights from Genome-Wide Association Studies

Alan R. Shuldiner, Regeneron Pharmaceuticals, Inc, USA
Genome-Wide Studies of Serum Lipids: Lessons from the Old Order Amish

Gary F. Lewis, Toronto General Hospital, Canada
ApoB Production - Human Gut and Liver

Michael Olivier, Medical College of Wisconsin, USA
Short Talk: Genomic and Proteomic Analysis of Human Dyslipidemia Characteristic of the Metabolic Syndrome

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
19:30—22:00
Poster Session 1

Jefferson/Madison

TUESDAY, JANUARY 12

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:15
TG-Rich Lipoproteins and Mechanisms of Atherosclerosis
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Bo Anders Angelin, Karolinska Institutet, Sweden

* Lars B. Nielsen, Rigshospitalet, University of Copenhagen, Denmark

Frank M. Sacks, Harvard School of Public Health, USA
Apolipoprotein C-III: Diverse Actions Contributing to Dyslipidemia and Atherosclerosis

Sudha B. Biddinger, Boston Children's Hospital, Harvard Medical School, USA
Deconvoluting the Metabolic Syndrome: The Role of Hepatic Insulin Resistance

John C. Rutledge, University of California, Davis, USA
Triglyceride-Rich Lipoproteins and Mechanisms of Inflammation and Atherosclerosis

Clay F. Semenkovich, Washington University School of Medicine, USA
Lipids and Stress Responses in the Evolution of Atherosclerosis

Dagmar Kratky, Medical University of Graz, Austria
Short Talk: Adipose Triglyceride Lipase Deficiency Affects Macrophage Morphology and Function and Significantly Reduces Atherosclerosis in LDLR(-/-) Mice

Nora Gray, University of California, Berkeley, USA
Short Talk: The Role of Angiopoietin-like 4 in Glucocorticoid-Regulated Lipid Metabolism

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Jefferson/Madison
11:15
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Jefferson/Madison
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Population Science on the Relationship between TG-Rich Lipoproteins and ASCVD
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Geesje M. Dallinga-Thie, Academic Medical Center, Netherlands

* Ruth McPherson, University of Ottawa Heart Institute, Canada

Michael H. Criqui, University of California, San Diego, USA
Population Studies of TG and ASCVD

Børge Nordestgaard, University of Copenhagen, Denmark
Non-Fasting TGs and CVD Risk

Elizabeth J. Parks, University of Missouri, USA
Dietary Influences on Triglyceride-Rich Lipoprotein Production

Carlos O. Mendivil, Harvard School of Public Health, USA
Short Talk: Tryglicerides in VLDL and LDL with apoC-III are a Strong Coronary Heart Disease Risk Factor when LDL Cholesterol is Low

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
19:30—22:00
Poster Session 2

Jefferson/Madison

WEDNESDAY, JANUARY 13

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:15
Therapeutics of Hypertriglyceridemia
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Mark W. Sleeman, Monash University, Australia

* Walter Singleton, Ionis Pharmaceuticals, Inc., USA

Rosanne M. Crooke, Ionis Pharmaceuticals, Inc., USA
Development of Novel Antisense Inhibitors for the Treatment of Hypertriglyceridemia

Dong Cheng, Bristol-Myers Squibb Company, USA
Are DGAT Inhibitors a Target for Triglyceride Lowering?

Matthew T. Flowers, University of Wisconsin, Madison, USA
Tissue-Specific Roles for SCD1 in Regulating Obesity

David Robert Neff, Merck, USA
The Potential Role of CETP Inhibition to Manage Dyslipidemia and CVD Risk

Mark Graham, Ionis Pharmaceuticals, Inc., USA
Short Talk: Antisense Inhibition of Angiopoietin-Like 3 in Rodent Models

Jennifer L. Lachey, Ember Therapeutics, USA
Short Talk: Treatment with a Soluble Activin Receptor Type IIB Attenuates Diet-Induced Obesity in High-Fat Diet-Fed Mice

09:20—09:40
Coffee Break

Lower Atrium
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Clinical Trials of Triglyceride Lowering and Outcomes
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA

* Robert H. Eckel, University of Colorado Denver, Anschutz Medical Campus, USA

Marshall B. Elam, University of Tennessee Health Science Center, USA
Fibrates and Cardiovascular Risk Reduction

Alan Chait, University of Washington School of Medicine, USA
Modalities of Triglyceride Lowering in the Prevention and Treatment of Cardiovascular Disease – Role of Niacin

Mahmood Hussain, SUNY Downstate Medical Center, USA
Regulation and Targeting of Microsomal Triglyceride Transfer Protein (MTP)

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
20:00—23:00
Entertainment

Jefferson/Madison

THURSDAY, JANUARY 14

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13HL099162-01




We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Bristol-Myers Squibb Company


Isis Pharmaceuticals, Inc.


Bristol-Myers Squibb Company


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676